P N Monk

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. ncbi Tetraspanins - gateways for infection
    Peter N Monk
    Department of Infection and Immunity, Medical School, University of Sheffield, Sheffield S10 2RX UK
    Infect Disord Drug Targets 12:4-17. 2012
  2. ncbi The human complement fragment receptor, C5L2, is a recycling decoy receptor
    Anne Marie Scola
    Academic Neurology Unit, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Mol Immunol 46:1149-62. 2009
  3. ncbi Function, structure and therapeutic potential of complement C5a receptors
    P N Monk
    Academic Neurology Unit, School of Medicine and Biomedical Science, University of Sheffield, Sheffield, UK
    Br J Pharmacol 152:429-48. 2007
  4. ncbi Selection of novel ligands from a whole-molecule randomly mutated C5a library
    S A Cain
    Krebs Institute of Biomolecular Science, Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield S10 2UH, UK
    Protein Eng 14:189-93. 2001
  5. ncbi Modulation of ligand selectivity by mutation of the first extracellular loop of the human C5a receptor
    S A Cain
    Section of Neurology, Division of Clinical Sciences, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Biochem Pharmacol 61:1571-9. 2001
  6. ncbi Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes
    T M Woodruff
    Department of Physiology and Pharmacology, University of Queensland, Australia
    Inflammation 25:171-7. 2001
  7. ncbi Mapping the ligand-binding site on the C5a receptor: arginine74 of C5a contacts aspartate282 of the C5a receptor
    S A Cain
    Department of Neurology, University of Sheffield Medical School, Sheffield S10 2RX, U K
    Biochemistry 40:14047-52. 2001

Collaborators

  • D P Fairlie
  • S A Cain
  • Anne Marie Scola
  • T M Woodruff
  • S D Sanderson
  • S M Taylor
  • Kay Ole Johswich
  • B Paul Morgan
  • Andreas Klos
  • A J Strachan
  • D M Williams
  • T Coughlan
  • V Harris
  • A K Wong

Detail Information

Publications7

  1. ncbi Tetraspanins - gateways for infection
    Peter N Monk
    Department of Infection and Immunity, Medical School, University of Sheffield, Sheffield S10 2RX UK
    Infect Disord Drug Targets 12:4-17. 2012
    ..Finally, the prospects of targeting tetraspanins for therapeutic intervention in infections caused by such pathogens are discussed...
  2. ncbi The human complement fragment receptor, C5L2, is a recycling decoy receptor
    Anne Marie Scola
    Academic Neurology Unit, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Mol Immunol 46:1149-62. 2009
    ..These data suggest that a major function of human C5L2 is to remove active complement fragments from the extracellular environment...
  3. ncbi Function, structure and therapeutic potential of complement C5a receptors
    P N Monk
    Academic Neurology Unit, School of Medicine and Biomedical Science, University of Sheffield, Sheffield, UK
    Br J Pharmacol 152:429-48. 2007
    ..This review will highlight major developments in C5a receptor research that support C5aR as an important therapeutic target. The intriguing possibilities raised by the existence of a non-signalling C5a receptor are also discussed...
  4. ncbi Selection of novel ligands from a whole-molecule randomly mutated C5a library
    S A Cain
    Krebs Institute of Biomolecular Science, Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield S10 2UH, UK
    Protein Eng 14:189-93. 2001
    ..Site-directed mutagenesis of the C-terminus of these variants resulted in the production of antagonists of C5adR(74) activity...
  5. ncbi Modulation of ligand selectivity by mutation of the first extracellular loop of the human C5a receptor
    S A Cain
    Section of Neurology, Division of Clinical Sciences, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Biochem Pharmacol 61:1571-9. 2001
    ..The complex effects of mutating these residues on the affinity and response to C5a, C5adR(74), and the peptide analogues provide evidence of different binding modes for these ligands on the C5aR...
  6. ncbi Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes
    T M Woodruff
    Department of Physiology and Pharmacology, University of Queensland, Australia
    Inflammation 25:171-7. 2001
    ....
  7. ncbi Mapping the ligand-binding site on the C5a receptor: arginine74 of C5a contacts aspartate282 of the C5a receptor
    S A Cain
    Department of Neurology, University of Sheffield Medical School, Sheffield S10 2RX, U K
    Biochemistry 40:14047-52. 2001
    ..These data indicate that the R(74) side chain of C5a makes an interaction with receptor D(282) that is responsible for the higher potency of intact C5a versus that of C5adR(74)...